These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24219012)

  • 1. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.
    Puig L; Strohal R; Fuiman J; Pedersen R; Szumski A; Koenig AS; Robertson D; Drexel H
    J Dermatolog Treat; 2014 Dec; 25(6):470-81. PubMed ID: 24219012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis.
    Puig L; Strohal R; Husni ME; Tsai TF; Noppakun N; Szumski A; Yang S; Robertson D; Boggs R; Koenig AS
    J Dermatolog Treat; 2015 Feb; 26(1):7-15. PubMed ID: 24283931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.
    Lestre S; Diamantino F; Veloso L; Fidalgo A; Ferreira A
    Eur J Dermatol; 2011; 21(6):916-20. PubMed ID: 21983007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
    BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
    Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
    BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.
    Campanati A; Ganzetti G; Di Sario A; Damiani A; Sandroni L; Rosa L; Benedetti A; Offidani A
    J Gastroenterol; 2013 Jul; 48(7):839-46. PubMed ID: 23065020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.
    Vender R; Lynde C; Gilbert M; Ho V; Sapra S; Poulin-Costello M
    J Cutan Med Surg; 2012; 16(6):407-16. PubMed ID: 23149196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
    Tyring S; Gottlieb A; Papp K; Gordon K; Leonardi C; Wang A; Lalla D; Woolley M; Jahreis A; Zitnik R; Cella D; Krishnan R
    Lancet; 2006 Jan; 367(9504):29-35. PubMed ID: 16399150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
    Thaçi D; Galimberti R; Amaya-Guerra M; Rosenbach T; Robertson D; Pedersen R; Yang S; Kuligowski M; Boggs R
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):900-6. PubMed ID: 23848989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
    Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
    Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.